SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Regeneron Pharmaceuticals
An SI Board Since May 1996
Posts SubjectMarks Bans Symbol
3557 104 0 REGN
Emcee:  Patrick Slevin Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
2682When was last time REGN disclose ABs target/candidate outside oncology? Is RGC Miljenko Zuanic-4/8/2019
2681One may premature conclude that ALNY/REGN ophthalmology (as part) collaboration Miljenko Zuanic14/8/2019
2680< (REGN retains primary responsibility for the ophthalmic component of the ALMiljenko Zuanic-4/8/2019
2679Who knows if these candidates will pan out? At least REGN is doing something to DewDiligence_on_SI-4/8/2019
2678REGN:ALNY alliance: investor.regeneron.com Latest ALNY presentation slides: Miljenko Zuanic-4/8/2019
2677High profile ophthalmologist-CMO (from Genentech) coming to ADVM: finance.yahoo.Miljenko Zuanic-4/1/2019
2676A bit odd...Felix B-3/26/2019
2675What is this (CEO), 100 shares out of 312.4K? secfilings.nasdaq.comMiljenko Zuanic-3/24/2019
2674Dermira's Lebrikizumab (from Roche) P2 in AD: finance.yahoo.com Placebo reMiljenko Zuanic-3/18/2019
2673REGN at JPM spring calls (transcript at SA): event.on24.com <We are trying tMiljenko Zuanic-3/16/2019
2672Interesting that in 2018 L-US growth 14% (due to pre-filled syringe) while E onlMiljenko Zuanic-3/14/2019
2671Finally, CMS drug spending (Par B too) for 2017 are out: portal.cms.gov Eylea:Miljenko Zuanic-3/14/2019
2670Small concern over Dupi in adolescent Ad/Asthma was initial/maintenance dose forMiljenko Zuanic-3/11/2019
2669REGN at Cowen, slides: seekingalpha.com Slide 5: Eyleay related, first time theMiljenko Zuanic-3/11/2019
2668Yes, 8 targets..4 selected already. All at research level.Miljenko Zuanic-3/4/2019
2667Is the REGN Avalanche collaboration still active? Haven't heard any updatesFelix B-3/4/2019
2666I will continue to *promote* ADVM, for those interested, recent (11/18) intervieMiljenko Zuanic-3/4/2019
2665Another AAV-GT acquisition, field ophthalmology (rare diseases): investors.biogeMiljenko Zuanic-3/4/2019
2664XBIT's Bermekimab (in AD): investors.xbiotech.com Data are interesting (forMiljenko Zuanic-3/2/2019
2663Is Bayer real, or cautious.... "And Bayer is tuning down its optimism on eMiljenko Zuanic-2/27/2019
2662New (and old) clouds on horizon. Deal or no deal, AMGN! What will it be like..Miljenko Zuanic-2/25/2019
2661New clinical data for Dupi, in CRSWNP : https://investor.regeneron.com/news-relMiljenko Zuanic-2/25/2019
2660From today Roche---> ONCE acquisition, everyone (or very wast majority) thinkMiljenko Zuanic12/25/2019
2659Lengthy, and interesting, presentation of the RGX-314 (anti -VEGF-fAb gene theraMiljenko Zuanic-2/21/2019
2658IP *wind* frequently change direction: https://investor.regeneron.com/news-releMiljenko Zuanic-2/15/2019
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News